Gossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed as Buy by Chardan Capital

Posted by Brenda Bartman on Oct 26th, 2026

Gossamer Bio (NASDAQ:GOSS – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a report released on Monday, Benzinga reports.

A number of other analysts also recently commented on GOSS. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a report on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $256.00.

Check Out Our Latest Analysis on GOSS

Gossamer Bio Stock Down 3.9%

NASDAQ:GOSS traded down $0.37 on Monday, hitting $9.23. The stock had a trading volume of 59,183 shares, compared to its average volume of 240,191. The business’s fifty day moving average is $11.48 and its 200 day moving average is $16.16. The company has a market cap of $56.40 million, a PE ratio of -0.16 and a beta of 2.21. Gossamer Bio has a 52 week low of $8.29 and a 52 week high of $309.60.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in shares of Gossamer Bio in the second quarter worth about $2,467,000. Kalehua Capital Management LLC purchased a new stake in shares of Gossamer Bio during the first quarter worth about $3,363,000. ARCH Venture Management LLC bought a new stake in Gossamer Bio during the 2nd quarter valued at approximately $1,326,004. BlackRock Inc. purchased a new position in Gossamer Bio in the 2nd quarter worth approximately $1,262,000. Finally, Corient Private Wealth LP bought a new position in Gossamer Bio in the 2nd quarter worth approximately $926,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.